Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab + Nivolumab + Lenvatinib in Advanced Hepatocellular Carcinoma
NCT07219459Phase 2Recruiting
- Sponsor
- CatalYm
- Start
- Mar 2026
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of visugromab in hepatocellular carcinoma (HCC), sponsored by CatalYm. Started Mar 2026; status: recruiting.
02
Drugs
visugromab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07219459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219459.